As 2020 draws to a close, it’s time to take a look back at some of the regulatory news that made headlines in December and look ahead at what’s in store for January 2021.
So far, 46 *novel drugs have secured the official stamp of FDA approval compared to 41 during the same period 2019. *Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.
Let's take a look at the biotech stocks awaiting FDA decision in December.
As of this writing, the FDA has approved 42 novel drugs so far this year compared to 33 during the same period (Jan – Oct) last year. Let’s take a look at the companies that await a ruling from the FDA in November.
Let’s take a look at the companies that await a ruling from the FDA in October.